In the second segment of this interview, Feldman discussed the importance of patient advocacy in clinical trial research.
Advertisement
Jorge Nieva, MD, explains new findings showing how steroids impact survival in patients undergoing ICI therapy.
Dr. Liu discusses the implications of the accelerated approval and what the future may hold.
Thorsten Füreder, MD, shares insights from the NSCLC cohort of the phase 2 trial.
Feldman presented on phase 2 patient-reported quality-of-life outcomes from the COCOON trial at the 2025 ASCO Annual Meeting.
The researchers explored the role of resilience in mediating the association between stigma and psychosocial adjustment.
Dr. Liu explains how these two studies are shaping standards of care and the treatment landscape in SCLC.
The systematic review examined interventions for improving patient function at any stage or phase of lung cancer.
The phase 3 study compared the efficacy data of benmelstobart plus anlotinib with that of pembrolizumab monotherapy.
Dr. Culver discusses the organization's work at ASCO and the importance of having a patient advocacy presence at the meeting.
The results of the interim analysis comparing safety and efficacy were presented at the 2025 ASCO Annual Meeting.